Clinical Trials and Associated Publications

Phase 2 Study to Assess the Effects of FX006 on Blood Glucose in Patients With Knee Osteoarthritis and Type 2 Diabetes

Phase 2 Study to Characterize the Systemic and Synovial PK of Triamcinolone Acetonide From FX006 in Patients With Knee Osteoarthritis (FX006-009)

Phase 3 Study of FX006 vs Normal Saline and Triamcinolone Acetonide for the Treatment of Patients With Knee Osteoarthritis (FX006-008)

Spitzer A, et al. Intra-articular injection of an extended-release formulation of triamcinolone acetonide provided significant improvement in pain, stiffness and function in patients with knee osteoarthritis. Presented as an oral at the AAHKS Annual Meeting, Friday, November 11, 2016. Paper #8.

Phase 2b Study of FX006 vs Normal Saline in Patients With Osteoarthritis of the Knee (FX006-006)

Conaghan P, et al. Sustained and profound analgesic benefits in people with osteoarthritis of the knee using FX006, an intra-articular extended-release formulation of triamcinolone acetonide: Results from a double-blind, randomized, parallel-group, dose-ranging study. Osteoarthritis Cartilage. 2016; 24:S49-S50. Abstract 70.

Phase 2 Study to Characterize the Local Duration of Triamcinolone Acetonide Exposure From FX006 in Patients With Knee Osteoarthritis (FX006-005)

Bodick N, et al. Prolonged joint residency of triamcinolone acetonide after an intra-articular injection of FX006, a sustained release formulation for the treatment of osteoarthritis. Osteoarthritis Cartilage. 2015; 23:A82-A416. Abstract 591.

Phase 2 PK and PD Study of FX006 in Patients with Knee Osteoarthritis (FX006-002)

Bodick N, et al. FX006 prolongs the residency of triamcinolone acetonide in the synovial tissues of patients with knee osteoarthritis. Osteoarthritis Cartilage. 2013; 21:S63-S312. Abstract 267.

Phase 2 Study of FX006 vs Triamcinolone Acetonide in Patients with Knee Osteoarthritis (FX006-001)

Bodick N, et al. An intra-articular, extended-release formulation of triamcinolone acetonide prolongs and amplifies analgesic effect in patients with osteoarthritis of the knee: a randomized clinical trial. J Bone Joint Surg Am. 2015; 97(11):877-88.

Bodick N, et al. Safety and efficacy of FX006 in patients with osteoarthritis of the knee. Osteoarthritis Cartilage. 2014; 22:S57-S489. Abstract 668.

Bodick N, et al. A randomized, double-blind, dose ranging study comparing FX006, an intra-articular sustained-release formulation of triamcinolone acetonide, to an approved injectable suspension of TCA in patients with osteoarthritis of the knee. Arthritis Rheumatol. 2013; 65(10): S1138. Abstract 2668.